Letermovir for CMV after kidney or pancreas transplant
Treatments studied
Part of Infections clinical trials.
This trial tests whether a drug called letermovir can safely treat CMV infection in people who have had a kidney or pancreas transplant. It is for those who are at high risk for CMV and whose own immune system cannot fight the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a kidney transplant or a kidney and pancreas transplant together.
- You were at high risk for CMV because the donor had CMV but you did not (D+/R-).
- You currently have a CMV infection in your blood that needs treatment.
- Your immune system is not able to fight CMV on its own, based on a test or your doctor's assessment.
- You are not pregnant or breastfeeding, and you are not taking part in a trial with another CMV drug or vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether letermovir can help prevent CMV (a common virus after transplant) from coming back after you’ve already been treated. If you qualify, you may be offered letermovir as “secondary prevention” and followed for about 6 months.
This trial tests if an oral medication called letermovir can prevent CMV infection in heart or lung transplant recipients who are at risk for CMV. It may offer a convenient option to protect against this virus after transplant.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
This study tests a drug called letermovir to prevent CMV infection after a kidney or liver transplant. It is for adults at moderate risk of CMV and may help keep you healthy after surgery.
This study compares two antiviral medications to prevent CMV (a common virus that can cause problems after kidney transplant) in people who had the virus before their transplant. The goal is to see which medicine works better and is safer for preventing CMV disease.
Hear when a new Cytomegalovirus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.